2van der Poll T, Marchant A, Buurman WA, et al. Endogenous IL-10 protects moci from death during septic peritonitis[ J]. J I mmunol, 1999,155( 11 ) :5397-5401.
3Hasko G, Virag L, Egnaczyk G, et al. The crucial role If IL-10 in the suppression of the immunological response in mice exposed to sraphylicoccal rnterotoxin B[ J]. Eur J I mmunol, 1998,28(4) : 1417-1425.
4Tan BB, Prewitt RL, Britt LD. Interleukin-10 prevents loss of rat skeletal muscle arterioles exoosed endotoxin [ J ]. Surg Res, 2001,100 ( 1 ) :110-115.
5Oku H, Nakazato H, Horikawa T. Pirfenidone suppresses tumor necrosis factor-alpha,enhances interleukin-10 and protects mice from endotoxic shock[J] .Eur J Pharmacol,2002,446(1-3) :167-176.
6Liaudet L, Mabley .IG, Sofiano FG, et d. Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture[ J]. Am J Bespir Cfit Care Med, 2001,164(7) :1213-1220.
7Grohmann U, Van-Snick J, Campanile F, et al. IL-9 protects mice from Gram-negetive bacterial shock: suppression of TNF-alpha, IL-12, and IFN-gamma, and induction of IL-10 [ J ]. J Immunol, 2000, 164 ( 8 ) :4197-4203.
8Lee TS, Chau LY. Nat Med. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin- 10 in mice [J ] . Nat Med, 2002,8 (3) :240-246.
9Gomez-Jimenez J, Martin MC, Samri R, et al. Interleukin-10 and the monocyte/macrophge induced inflannatory response in septic shock[ J] .J Infect Dis, 1995,171(2) :472-475.
10Junger WG, Hoyt DB, Liu FC, et al. Immunosuppression after endotoxin shock: the result of multiple anti-inflammatory factors [ J ]. J Trauma,1996,40(5) :702-709.
同被引文献49
1Macis G, Salcuni M, Cotroneo AR, et al. Pulmonary thromboembolism and diagnostic imaging:integration of techniques and methods. Radiol Med Torino, 1996; 92(1-2):63-71.
2Eftychiou v. Clinical diagnosis and manegement of the patient with deep venous thrombolism and pulmon embolism. Nurse Pract. 1996; 21:50.
3Anderson FAJ, Wheeler HB, Goldberg RJ, et al. A population-based of the hospital incidence and case- fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991; 151: 933-938.
4Wakefield TW, Strieter RM, Prince MR, et al. Pathogenesis of venous thrombosis-A new insight. Cardiovasc Surg. 1997; 5:6-15.
5Sullivan VV, Hawley AE, Farris DM, et al. Decrease in fibrin content of venous thrombi in selectin-deficient mice. J Surg Res. 2003; 109(1): 1-7.
7Lowe G, Rumley A, Woodward M, et al. C-reactive protein, idiopathic venous thromboembolism and hormone replacement therapy. Thromb Haemost. 2000; 84(4):730-731.
8Londy FJ, Kadell AM, Wrobleski SK, et al. Detection of perivenous inflammation in a rat model of venous thrombosis using MRV. J Invest Surg. 1999; 12(3):151-156.
9Downing LJ, Strieter RM, Kadell AM, et al. J Immunol. 1998; 161(3):1471-1476. IL-10 regulates thrombus-induced vein wall inflammation and thrombosis.
10Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 2002; 113(8): 636-642.
